Summary
Global Market Direct’s pharmaceuticals report, “Stiefel Laboratories - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.
Scope
- Stiefel Laboratories - company overview including business description, key employees, and other facts.
- Review of current pipeline of Stiefel Laboratories human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Stiefel Laboratories with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Stiefel Laboratories’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Stiefel Laboratories’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Stiefel Laboratories in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Stiefel Laboratories’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Stiefel Laboratories.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Stiefel Laboratories and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
Global Market Direct’s pharmaceuticals report, “Stiefel Laboratories - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.
Scope
- Stiefel Laboratories - company overview including business description, key employees, and other facts.
- Review of current pipeline of Stiefel Laboratories human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Stiefel Laboratories with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Stiefel Laboratories’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Stiefel Laboratories’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Stiefel Laboratories in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Stiefel Laboratories’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Stiefel Laboratories.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Stiefel Laboratories and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 list of Figures
2 INTRODUCTION
3 STIEFEL LABORATORIES SNAPSHOT
3.1 Business Description
4 STIEFEL LABORATORIES- RESEARCH AND DEVELOPMENT OVERVIEW
4.1 Key Therapeutic Areas
5 STIEFEL LABORATORIES- PIPELINE REVIEW
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 STIEFEL LABORATORIES PIPELINE PRODUCTS GLANCE
6.1 Stiefel Laboratories Phase II Pipeline
6.2 Stiefel Laboratories Phase I Pipeline
6.3 Stiefel Laboratories Pre-Clinical Pipeline
7 STIEFEL LABORATORIES - DRUG PROFILES
7.1 Product
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 STIEFEL LABORATORIES PIPELINE ANALYSIS
8.1 Stiefel Laboratories Pipeline Products by Therapeutic Class
8.2 Stiefel Laboratories Pipeline Products by Target
8.3 Stiefel Laboratories Pipeline by Route of Administration
8.4 Stiefel Laboratories Pipeline Products by Molecule Type
9 STIEFEL LABORATORIES- RECENT PIPELINE UPDATES
10 STIEFEL LABORATORIES- DORMANT PIPELINE PROJECTS
10.1 Feature on Dormant Projects
11 STIEFEL LABORATORIES- DISCONTINUED PIPELINE PRODUCTS
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product
12 STIEFEL LABORATORIES – FEATURED NEWS
13 STIEFEL LABORATORIES STATEMENT
13.1 Stiefel Laboratories - Locations and Subsidiaries
14 APPENDIX
14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer
LIST OF TABLES
Table 1: Stiefel Laboratories - Key Information
Table 2: Stiefel Laboratories - Key Facts
Table 3: Stiefel Laboratories - Key Therapeutic Areas
Table 4: Stiefel Laboratories - Pipeline by Stage of Development,
Table 5: Stiefel Laboratories - Monotherapy Products in Pipeline,
Table 6: Stiefel Laboratories - Combination Treatment Modalities in Pipeline,
Table 7: Stiefel Laboratories - Phase II Pipeline,
Table 8: Stiefel Laboratories - Phase I Pipeline,
Table 9: Stiefel Laboratories - Pre-Clinical Pipeline,
Table 10: Stiefel Laboratories - Pipeline By Therapeutic Class
Table 11: Stiefel Laboratories - Pipeline By Target
Table 12: Stiefel Laboratories - Pipeline By Route of Administration
Table 13: Stiefel Laboratories - Pipeline By Molecule Type
Table 14: Stiefel Laboratories - recent Pipeline Updates
Table 15: Stiefel Laboratories - Dormant Pipeline Projects
LIST OF FIGURES
Figure 1: Stiefel Laboratories - Research and Development Overview
Figure 2: Stiefel Laboratories - Pipeline by Stage of Development,
Figure 3: Stiefel Laboratories - Monotherapy Products in Pipeline,
Figure 4: Stiefel Laboratories - Combination Treatment Modalities in Pipeline,
Figure 5: Stiefel Laboratories - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Stiefel Laboratories - Pipeline By Therapeutic Class
Figure 7: Stiefel Laboratories - Pipeline By Target and Stage of Development
Figure 8: Stiefel Laboratories - Pipeline By Target
Figure 9: Stiefel Laboratories - Pipeline By Route of Administration and Stage of Development
Figure 10: Stiefel Laboratories - Pipeline By Route of Administration
Figure 11: Stiefel Laboratories - Pipeline By Molecule Type and Stage of Development
Figure 12: Stiefel Laboratories - Pipeline By Molecule Type
COMPANIES MENTIONED
Stiefel Laboratories
1.1 List of Tables
1.2 list of Figures
2 INTRODUCTION
3 STIEFEL LABORATORIES SNAPSHOT
3.1 Business Description
4 STIEFEL LABORATORIES- RESEARCH AND DEVELOPMENT OVERVIEW
4.1 Key Therapeutic Areas
5 STIEFEL LABORATORIES- PIPELINE REVIEW
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 STIEFEL LABORATORIES PIPELINE PRODUCTS GLANCE
6.1 Stiefel Laboratories Phase II Pipeline
6.2 Stiefel Laboratories Phase I Pipeline
6.3 Stiefel Laboratories Pre-Clinical Pipeline
7 STIEFEL LABORATORIES - DRUG PROFILES
7.1 Product
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 STIEFEL LABORATORIES PIPELINE ANALYSIS
8.1 Stiefel Laboratories Pipeline Products by Therapeutic Class
8.2 Stiefel Laboratories Pipeline Products by Target
8.3 Stiefel Laboratories Pipeline by Route of Administration
8.4 Stiefel Laboratories Pipeline Products by Molecule Type
9 STIEFEL LABORATORIES- RECENT PIPELINE UPDATES
10 STIEFEL LABORATORIES- DORMANT PIPELINE PROJECTS
10.1 Feature on Dormant Projects
11 STIEFEL LABORATORIES- DISCONTINUED PIPELINE PRODUCTS
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product
12 STIEFEL LABORATORIES – FEATURED NEWS
13 STIEFEL LABORATORIES STATEMENT
13.1 Stiefel Laboratories - Locations and Subsidiaries
14 APPENDIX
14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer
LIST OF TABLES
Table 1: Stiefel Laboratories - Key Information
Table 2: Stiefel Laboratories - Key Facts
Table 3: Stiefel Laboratories - Key Therapeutic Areas
Table 4: Stiefel Laboratories - Pipeline by Stage of Development,
Table 5: Stiefel Laboratories - Monotherapy Products in Pipeline,
Table 6: Stiefel Laboratories - Combination Treatment Modalities in Pipeline,
Table 7: Stiefel Laboratories - Phase II Pipeline,
Table 8: Stiefel Laboratories - Phase I Pipeline,
Table 9: Stiefel Laboratories - Pre-Clinical Pipeline,
Table 10: Stiefel Laboratories - Pipeline By Therapeutic Class
Table 11: Stiefel Laboratories - Pipeline By Target
Table 12: Stiefel Laboratories - Pipeline By Route of Administration
Table 13: Stiefel Laboratories - Pipeline By Molecule Type
Table 14: Stiefel Laboratories - recent Pipeline Updates
Table 15: Stiefel Laboratories - Dormant Pipeline Projects
LIST OF FIGURES
Figure 1: Stiefel Laboratories - Research and Development Overview
Figure 2: Stiefel Laboratories - Pipeline by Stage of Development,
Figure 3: Stiefel Laboratories - Monotherapy Products in Pipeline,
Figure 4: Stiefel Laboratories - Combination Treatment Modalities in Pipeline,
Figure 5: Stiefel Laboratories - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Stiefel Laboratories - Pipeline By Therapeutic Class
Figure 7: Stiefel Laboratories - Pipeline By Target and Stage of Development
Figure 8: Stiefel Laboratories - Pipeline By Target
Figure 9: Stiefel Laboratories - Pipeline By Route of Administration and Stage of Development
Figure 10: Stiefel Laboratories - Pipeline By Route of Administration
Figure 11: Stiefel Laboratories - Pipeline By Molecule Type and Stage of Development
Figure 12: Stiefel Laboratories - Pipeline By Molecule Type
COMPANIES MENTIONED
Stiefel Laboratories
